Pulmonology Procedures |

Bronchoscopic Diagnosis of a Parenchymal Non-Small Cell Lung Cancer (NSCLC) With Regional Adenoapthy - Benefit of Comprehensive Tissue Sampling and Staging FREE TO VIEW

Yuan Zhang*, MD; Yan Shang, MD; Mingying Zeng, MD; Rex Yung, MD
Author and Funding Information

Johns Hopkins University School of Medicine, Baltimore, MD

Chest. 2012;142(4_MeetingAbstracts):872A. doi:10.1378/chest.1387621
Text Size: A A A
Published online


SESSION TYPE: Endobronchial Ultrasound

PRESENTED ON: Monday, October 22, 2012 at 04:00 PM - 05:30 PM

PURPOSE: Accurate NSCLC tissue staging is critical to guide multi-modality therapy, including induction chemotherapy for stage II/III diseases. Fiberoptic bronchoscopy (FOB) is a minimally invasive technique used for LC diagnosis since 1969. Recent advances in navigational bronchoscopy and in Endobronchial-Ultrasound guided transbronchial needle-aspiration (EBUS-TBNA) of lymph nodes(LC) have improved diagnostic accuracy for peripheral and nodal stations respectively. There is debate whether both “primary” parenchymal lesions and regional nodes should be simultaneously sampled. We present a NSCLC series to determine the utility of such comprehensive tissue sampling.

METHODS: Review of IRB approved prospective FOB cases evaluating role of image-guided interventions in managing suspected thoracic malignancies. Between 11-2009 to 03-2012, 203 patients had bronchoscopy for possible thoracic malignancies. Of the bronchoscopically proven 103 LC cases, 93 were NSCLC. Excluding 9 central tumors, 84 cases has a peripheral lung primary (PLP). Of these 49 cases also had adenopathy and had both EBUS-TBNA and attempted sampling of peripheral mass by transbronchial biopsy (TBBX), transbronchial brushing or peripheral TBNA. These 49 cases with pathology confirmed diagnosis of NSCLC were analyzed.

RESULTS: The diagnostic yields of PLP sampling and EBUS-TBNA LN staging were 87.76% and 69.39% respectively. 57.14%(28/49) were positive in both sample sets. 12.24% (6/49) were diagnosed only by nodal sampling (unable to reach primary) and 30.61% (15/49) were diagnosed only by PLP sampling (benign reactive adenopathy or unsuccessful LN sampling).

CONCLUSIONS: In spite of advances in real-time (EBUS-TBNA) and image-guided navigational bronchoscopies, not all primary peripheral lesions can be reached and visualizing apparent EBUS-TBNA puncture of LN may yield only reactive lymphocytes or non-diagnostic cells. Unless bedside cytology assessment is 100% accurate, multi-target sampling will reduce need for repeat procedures.

CLINICAL IMPLICATIONS: Improvement in NSCLC outcome depending on nodal staging and promise of personalized therapies depends on definitive NSCLC cell-type and molecular mutation analysis. This may be best accomplished by comprehensive nodal sampling and harvesting adequate tumor tissue at time of bronchoscopy to test for a growing array of predictive and prognostic biomarkers.

DISCLOSURE: The following authors have nothing to disclose: Yuan Zhang, Yan Shang, Mingying Zeng, Rex Yung

No Product/Research Disclosure Information

Johns Hopkins University School of Medicine, Baltimore, MD




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543